Virology Research Services Chooses Discovery Park as it relocates London team

A leading virus-focused consultancy and experimental service provider working to accelerate vaccine and virus research efforts has relocated its laboratory and consultancy services to Discovery Park in Kent.

Virology Research Services (VRS), founded in 2017 by Michela Mazzon and Chiara Mencarelli, provides high-level testing and analysis services to industry and academia. The business began with the founders providing testing services to small biotech and to the academic community and has grown from there to a team of seven.

Virology Research Services now provides a range of services to support the work of scientists in pharma, industry, and academia, supporting vaccine development and antiviral drug discovery.

Virology Research Services selected Discovery Park as its new home thanks to access to high quality laboratories which meet its need for high-containment infrastructures for use with multiple viral systems.

The business has attracted a significant number of new clients and a wider portfolio of experiments and services. It requires state-of-the-art facilities to enable it to carry out research for start-ups to multi-national companies. Virology Research Services has taken a CAT2 laboratory and is planning to open a specialist CAT3 facility to allow it to work with higher-risk biological agents and hazards.

Focusing on the what the future holds, Michela Mazzon, co-founder and Joint Managing Director, said: “The need for space and specialist facilities to grow the business made the move a necessity. We needed to be somewhere that could accommodate our future business plans.

A real driver of our decision was being part of an ambitious and thriving life sciences community.

Chiara Mencarelli, Managing Director, added: “Discovery Park has a focus on collaboration. We are keen to work closely with other scientists and personnel involved in the life science ecosystem to share knowledge, expertise, and identify solutions to today’s most pressing problems.

Discovery Park is an ideal fit for companies like us seeking collaboration, networking, and access to support services. We are keen to give our growing staff the opportunity to network and feel part of a wider science community in the UK.

Being based at Discovery Park gives the partners the opportunity to consider programmes to help support them to scale-up and develop their business model. The team can also take advantage of the recently announced Skills Hub at Discovery Park, which will support the growing team at Virology Research Services and encourage highly qualified candidates to enter the sector.

Mayer Schreiber, CEO at Discovery Park, said: “We have a thriving list of tenants creating a huge talent pool and opportunity for all the businesses that locate here.

The team at Virology Research Services is a welcome addition to our science community. We are confident they will go from strength to strength. They will be able to support their impressive list of clients and have the space to grow and strengthen their connections within the collaborative environment we provide.”

Discovery Park has witnessed a surge in demand for laboratory space due to the lack of available facilities in London and the Golden Triangle.

For further information on VRS visit: www.virologyresearchservices.com or visit www.Discovery-Park.co.uk


 

More news and updates

Abzena launches EpiScreen® 2.0, a next-generation immunogenicity tool for de-risking the development of complex biologics

Abzena has announced the launch of its enhanced hashtag#bioassay platform EpiScreen® 2.0, a comprehensive suite of assays that predict and evaluate potential risks of preclinical hashtag#immunogenicity in protein, antibody, and gene therapy therapeutics.

University of Oxford spin-out revealed as winner of ‘Golden Ticket’ programme for planetary health innovations

University of Oxford spin-out HydRegen has been revealed as the winner of a programme designed to recognise innovations in planetary health created by Pioneer Group in partnership with CPI.

CHAIN Biotech collaborates with German Cancer Research Center on development of a novel oncology vaccine

CHAIN Biotechnology Ltd and the German Cancer Research Center (DKFZ) have signed an agreement to collaborate on the development of therapeutic cancer vaccines for indications caused by Human Papillomavirus (HPV).

Macomics unveils its lead first-in-class anti-pan-LILRB monoclonal antibody programme with positive pre-clinical data

Macomics’ lead programme, MACO-355, in IND enabling studies is a ligand-blocking independent pan-LILR monoclonal antibody for the treatment of cancer.

More within